PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies
By
Lingli Ma
Ning Hou
Xiaoyu Zhao
Zimeng Li
Qing Liu
Jianyu Zhao
Qing Wang
June 19, 2026
Clinical Scorecard: Understanding PANoptosis in Diabetic Retinopathy: Immunological Mechanisms and Potential Therapeutic Approaches
At a Glance
Category Detail
Condition Diabetic Retinopathy Key Mechanisms PANoptosis, oxidative stress, inflammation, programmed cell death Target Population Diabetic patients, particularly those with retinal complications Care Setting Ophthalmology and diabetes management clinics
Key Highlights
PANoptosis integrates apoptosis, pyroptosis, and necroptosis in DR progression. Hyperglycemia-induced oxidative stress is a key driver of retinal neurodegeneration. Emerging biomarkers related to PANoptosis may aid in diagnosis and treatment. Therapeutic strategies should focus on localized, biomarker-guided interventions. Challenges include blood-retinal barrier penetration and systemic immune side effects. Guideline-Based Recommendations
Diagnosis
Utilize PANoptosis-related gene signatures as potential biomarkers. Management
Prioritize localized delivery of PANoptosis inhibitors and other therapeutic agents. Monitoring & Follow-up
Conduct longitudinal biomarker cohort studies to track disease progression. Risks
Consider potential safety risks of non-selective PANoptosis blockade. Patient & Prescribing Data
Patients with diabetic retinopathy and associated complications.
Focus on small-molecule inhibitors and gene interventions targeting PANoptosis.
Clinical Best Practices
Implement cell-type-specific modulation of PANoptosis pathways. Adopt a time-dependent approach to intervention based on disease stage. Related Resources & Content
